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Abstract Decreased systolic function is a central factor in
the pathogenesis of heart failure, yet there are no safe
medical therapies to improve cardiac function in patients.
Currently available inotropes, such as dobutamine and
milrinone, increase cardiac contractility at the expense of
increased intracellular concentrations of calcium and cAMP,
contributing to increased heart rate, hypotension, arrhyth-
mias, and mortality. These adverse effects are inextricably
linked to their inotropic mechanism of action. A new class of
pharmacologic agents, cardiac myosin activators, directly
targets the kinetics of the myosin head. In vitro studies have
demonstrated that these agents increase the rate of effective
myosin cross-bridge formation, increasing the duration and
amount of myocyte contraction, and inhibit non-productive
consumption of ATP, potentially improving myocyte energy
utilization, with no effect on intracellular calcium or cAMP.
Animal models have shown that this novel mechanism
increases the systolic ejection time, resulting in improved
stroke volume, fractional shortening, and hemodynamics
with no effect on myocardial oxygen demand, culminating
in significant increases in cardiac efficiency. A first-in-
human study in healthy volunteers with the lead cardiac
myosin activator, CK-1827452, as well as preliminary
results from a study in patients with stable chronic heart
failure, have extended these findings to humans, demon-
strating significant increases in systolic ejection time,
fractional shortening, stroke volume, and cardiac output.
These studies suggest that cardiac myosin activators offer
the promise of a safe and effective treatment for heart fail-
ure. A program of clinical studies are being planned to test
whether CK-1827452 will fulfill that promise.
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Introduction
Heart failure is the primary reason for admission in greater
than 1 million hospitalizations in the United States alone
[1] and 65–70% of these patients have at least a mild
decrease in systolic dysfunction [2]. The central role of
ventricular dysfunction in the pathogenesis of heart failure
has been recognized explicitly for over 50 years, and
implicitly since Dr. William Withering’s application of the
foxglove treatment (digitalis) developed by an elderly
woman in Shropshire, England over 200 year ago. While
the neurohormonal model has appropriately emerged as a
dominant factor in understanding chronic heart failure,
cardiac dysfunction remains a primary and necessary
instigating event. In the setting of acute heart failure,
altered hemodynamics continue to be a primary target for
therapies. Testament to the necessity of these agents may
be found in the continued use of intravenous agents with
inotropic properties that are known to have significant
adverse effects, such as dobutamine and milrinone, [3] and
the continued active development of both intravenous and
oral agents despite scores of failures. This review will
discuss the development of a novel class of agents designed
to improve cardiac performance, known as cardiac myosin
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activators, in the context of the mechanism of cardiac
contraction and the currently available agents.
Mechanisms to improve cardiac performance
An in-depth explication of the mechanism of cardiac per-
formance is beyond the scope of this review. However,
understanding certain elements of myocardial contractility
is essential to appreciate how cardiac myosin activators
might be useful in the treatment of heart failure. Myocar-
dial contraction is the result of a remarkable transduction of
chemical energy into mechanical energy that is regulated
on a beat-to-beat basis by inter-related signaling pathways
acting on the sarcomere, or the contractile unit of the
myocyte [4]. Sarcomeres have a complicated structure with
the main force-generating unit consisting of actin, myosin,
and multiple regulatory proteins (such as troponin and
tropomyosin). The myosin complex consists of two myosin
heavy chains and two pairs of myosin light chains. The
myosin heavy chain has a globular head that has an ATPase
domain (which cleaves ATP to produce energy), as well as
an actin-binding site, through which the contractile force is
transduced. Cardiac troponin (cTn) and tropomyosin form
a complex that regulates the interaction of myosin with
actin in a calcium sensitive manner [5]. In the resting state,
there are low calcium concentrations in the myocyte, and
the troponin–tropomyosin complex blocks cross-bridge
formation between actin and myosin. Depolarization of the
myocyte triggers calcium release from the sarcoplasmic
reticulum, increasing sarcomeric concentrations of cal-
cium, resulting in calcium binding to cTnC and a shift of
tropomyosin so that it no longer blocks actin–myosin cross-
bridge formation. Subsequently, myosin binds to actin and,
from energy released through the hydrolysis of ATP to
ADP, produces a force-generating conformational change
and shortening of the sarcomere. Calcium is actively
transported back into the sarcoplasmic reticulum in a
highly energy-intensive process, awaiting release again
after the next depolarization event, a cycle that repeats for
the lifetime of the organism.
The cardiac actin–myosin cycle [6, 7] is central to this
process of myocardial force generation and continued
research has elucidated important details of the cycle
(see Fig. 1) which are very important to a discussion of
cardiac myosin activators. The linking of mechanical and
enzymatic cycles of the myosin motor has been the subject
of intense investigation for decades culminating in a well-
accepted model depicted in Fig. 1. After the binding of
ATP to myosin (Fig. 1, Step 1), the myosin head rapidly
dissociates from actin. Myosin rapidly hydrolyzes the
bound ATP into ADP and Pi (Fig. 1, Step 2), which allows
a weak interaction between the myosin head and actin as it
scans for a proper binding site (Fig. 1, Step 3). On binding,
the actin–myosin–ADP–Pi complex undergoes an activa-
tion step (the slowest step in the overall cycle) which
simultaneously converts the complex to a strongly bound
state and releases the Pi (Fig. 1, Step 4). The release of the
Pi results in the transduction step with a conformational
‘‘bending’’ of the myosin head, producing approximately a
10-nm stroke (Fig. 1, Step 5). Subsequently, the release of
ADP occurs and the exit from the strongly bound state
(Fig. 1, Step 6) is triggered by the rapid binding of ATP to
the myosin complex which leads to its dissociation from
actin and prepares the cycle to repeat. Two aspects of this
cycle are important to note. First, the rate-limiting step in
cross-bridge formation and thus, the number of available
cross bridges per depolarization (heart beat), is the transi-
tion from the weakly bound to the strongly bound state of
the actin–myosin complex (Fig. 1, Step 4). Second, ATP is
hydrolyzed independent of actual mechanical work (Fig. 1,
Step 2) and if there is subsequent actin-independent release
of the Pi, no force-generating stroke is produced. A portion
of cardiac myosin ATP hydrolysis, or energy consumption,
does not result in strong actin–myosin binding and is thus
wasted although the rate of actin independent ATP
hydrolysis is thought to be slow.
‘‘Inotrope’’ versus cardiac myosin activator
Inotropy may be considered an intrinsic or directly evoked
improvement of myocardial contractility, as measured by
Fig. 1 The actin–myosin cycle (Modified from [6])
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indices of force and the rate of change in variables of
ventricular contraction (e.g., volume, pressure, force). The
current drugs that target an increase of myocardial con-
tractility share a similar mechanism of action: they increase
intracellular cAMP and ultimately calcium (Fig. 2). Cate-
cholamines (isoproterenol, norepinephrine, dobutamine,
dopamine) increase cAMP through receptor-mediated
increases in cAMP production with multiple downstream
signaling effects. Phosphodiesterase (PDE) inhibitors pre-
vent the degradation of cAMP and consequently also
increase intracellular concentrations. Both of these mech-
anisms result in increased intracellular calcium, which in
myocytes increases contractility but with significant costs.
The increased intracellular calcium needs to be actively
transported back into the sarcoplasmic reticulum with each
cardiac cycle, markedly increasing the ATP required to
maintain calcium homeostasis. This increased energy uti-
lization results in increased myocardial oxygen demand.
Myocardial oxygen demand is further exacerbated by an
increased heart rate. Elevations in intracellular calcium
concentrations and increased calcium transients are also
considered to play a role in the increased arrhythmoge-
nicity of these agents. These effects contribute to the
observed clinical increase in arrhythmias and mortality
with these drugs, especially in the setting of myocardial
ischemia [8–11]. All of the currently available agents with
inotropic properties also have significant vascular effects,
predominantly vasodilation in the case of dobutamine and
milrinone. The hypotensive effects of dobutamine and
milrinone are particularly dangerous in the very patients in
whom these agents are indicated [9, 10]. The challenge for
these inodilator agents is that the adverse effects are
directly related to and a consequence of their inotropic
mechanism of action.
As the details of the actin–myosin cycle were eluci-
dated, a potential new approach to increasing cardiac
performance emerged. Small molecules that could activate
cardiac myosin would theoretically be able to improve the
ability of the heart to perform work without altering
intracellular cAMP or calcium transients. Ideally, an agent
would increase the rate-limiting step in the actin–myosin
cycle by increasing the transition from the weakly bound to
the strongly bound state (Fig. 1, Step 4), allowing more
myosin heads to be active during each heart beat. In
addition, if an agent could decrease the actin-independent
release of Pi, it would improve myocardial efficiency.
A useful analogy for these effects is to picture a multi-
oared rowboat or racing shell where some of the crew
stroke with their oars out of the water; a cardiac myosin
activator would result in more oars in the water and fewer
oars stroking out of the water. In the absence of incurring
additional energetic costs related to calcium cycling, this
mechanism would be the most efficient way of increasing
cardiac contractility.
Pre-clinical development of cardiac myosin
activators
Starting with a biochemically reconstituted sarcomere to
screen in high throughput fashion for small molecule
activators of the cardiac sarcomere, a group of biologists
Fig. 2 Schematic of myocyte
and signaling pathways
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led by Dr. Fady Malik, pursued the hypothesis and reported
that cardiac myosin activators could improve cardiac per-
formance [12]. The initial hit compounds discovered with
this assay were subsequently optimized in an iterative
fashion using biochemical assays in conjunction with
assessment of contractility in cardiac myocytes. In parallel,
the compounds were optimized for drug-like properties
(e.g., drug metabolism, pharmacokinetics, solubility), and
undesirable activities were ruled out (such as phosphodi-
esterase III activity and alterations in calcium transients).
Ultimately, the best compounds were characterized using
in vivo models of cardiac function (rat and dog). Four
compounds emerged from this process for which public
pre-clinical data are available, one of which has progressed
into human clinical development.
Data presented from three pre-clinical compounds sup-
ported the hypothesis that cardiac myosin activators could
improve cardiac performance independent of changes in the
calcium transient. CK-0689705 [13] did not increase cal-
cium transients in isolated rat ventricular myocytes, but did
increase fractional myocyte shortening in a dose-dependent
manner. Interestingly, despite these increases in contractil-
ity, CK-0689705 did not increase the velocity of contraction,
in contrast to classic inotropes, such as isoproterenol, which
increase contraction velocity and calcium transients. Fur-
thermore, the effect of CK-0689705 on cardiac function was
preserved in myocytes from rats with heart failure due
to myocardial infarction, in contrast to the decreased
responsiveness observed with the beta-adrenergic agonist,
isoproterenol.
The second pre-clinical compound, CK-1122534, also
supported the hypothesis of cardiac myosin activation.
CK-1122534 [14] activated the ATPase of the motor-
domain of cardiac myosin (the S1 subunit) in three test
systems, using purified cardiac actin and cardiac S1, a
calcium-regulated system composed of cardiac S1 and a
reconstituted thin filament, and skinned cardiac myofibrils.
This myosin activity was confirmed to be cardiac specific,
with no effect on skeletal or smooth muscle myosins.
Transient kinetic methods were used to demonstrate that
CK-1122534 increased by two-fold the rate of actin-
dependent Pi release, a measure of the transition from the
weakly bound to the strongly bound state (Fig. 1, Step 4)
without affecting the rates of other steps in the cycle. In
addition, CK-1122534 was shown to overcome the inhib-
iting effects of BDM (2,3-butanedione-2-monoxime) and
blebbistatin on the contractility of cardiac myocytes. Both
BDM and blebbistatin [15] inhibit myosin activity by
uncoupling myosin–actin cross-bridge contractility from
the calcium transient. Thus, at high concentrations of these
inhibitors, there is no contractility despite persistent
cycling of the calcium transient. CK-1122534 partially
restored myocyte contractility in the setting of marked
inhibition by both BDM and blebbistatin, also supporting
its role as a direct myosin activator. As with CK-0689705,
CK-1122534 was also demonstrated to have no phospho-
diesterase activity and to not alter calcium transients, while
increasing myocyte fractional shortening, even in the
presence of beta-adrenergic blockade with propranolol
[16].
The third pre-clinical compound, CK-1213296, extended
these observations into animal models of heart failure [17].
As with the previously mentioned agents, CK-1213296 was
active in multiple experimental systems, increasing the
ATPase activity of cardiac myosin specifically without
affecting calcium transients. In addition, CK-1213296 was
shown to increase actin-dependent Pi release (Fig. 1, Step 4),
facilitating the transition from the weak-to-the-strong bind-
ing state, as well as to decrease the rate of actin-independent
phosphate release, reducing non-productive and hence
wasteful hydrolysis of ATP. In anesthetized Sprague-
Dawley rats, CK-1213296 increased cardiac fractional
shortening by 25% (12% absolute increase), as assessed by
echocardiography. In another series of experiments (Fig. 3),
mongrel dogs were chronically instrumented with pressure
transducers in the left ventricle (LV), left atrium, and aorta,
with ultrasound crystals implanted for measurement of LV
dimensions and wall thickness, and in some dogs, with an
aortic flow probe and inferior vena caval occluder to assess
pressure–volume loops. The dogs underwent myocardial
infarction using a left anterior descending artery occluder
followed by continuous rapid ventricular pacing (220–
240 bpm) to produce heart failure. Hemodynamic assess-
ments were made at 5–6 weeks after the infarction procedure
and the pacemaker was turned off during these measure-
ments. The dogs demonstrated clear evidence of heart failure
with increases in resting heart rate and left atrial pressure,
and marked decreases in mean arterial pressure, dP/dt,
cardiac output, stroke volume, and fractional shortening.
Administration of a bolus followed by an infusion of
CK-1213296 resulted in significant improvements in cardiac
function (end-systolic elastance, stroke volume, wall thick-
ening, fractional shortening), associated with decreased
filling pressures (left atrial pressure) and heart rate. Thus,
these experiments with CK-1213296 fulfilled the therapeutic
hypothesis that cardiac myosin activators could improve
cardiac performance in the setting of heart failure.
Development of the cardiac myosin activator,
CK-1827452
The previous candidate compounds provided essential
experience for the development of the cardiac myosin
activator, CK-1827452 (Fig. 4). CK-1827452 increases
cardiac myosin ATPase activity in a dose-dependent
292 Heart Fail Rev (2009) 14:289–298
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manner that is selective for cardiac myosin versus non-
cardiac myosins and is independent of the sarcomeric
regulatory proteins. As seen with previous myosin activa-
tors, CK-1827452 accelerates productive phosphate release
(actin-dependent Pi release; Fig. 1, Step 4), increasing the
transition from the weak to the strong binding state, while
inhibiting non-productive phosphate release (actin-inde-
pendent phosphate release), hence reducing wasted ATP
hydrolysis [18, 19]. In cellular preparations, this compound
markedly increased myocyte contraction with an associated
increase in the time-to-peak contraction, indicating an
increased duration of contraction. This finding is a hall-
mark of these agents where contraction velocity is largely
unaltered, but the time spent contracting is increased.
Despite these increases in contractility, there are no chan-
ges in the calcium transient and there is no alteration of the
sarcoplasmic reticulum calcium content or in the sodium
calcium exchanger [20]. CK-1827452 was also able to
overcome the inhibition of cross-bridge formation by BDM
without increasing the calcium transient magnitude and had
no evidence of phosphodiesterase activity [21]. All of these
studies confirmed that the mechanism of action of
CK-1827452 as a specific cardiac myosin activator, but
additional studies in animals demonstrated its potential
clinical efficacy.
The in vivo efficacy of CK-1827452 was studied in two
animal species. In anesthetized Sprague-Dawley rats,
infusion with the agent acutely increased LV fractional
shortening by 20% in a dose-dependent manner with no
significant effect on diastolic diameter, as assessed by two-
dimensional guided M-mode echocardiography. Another
group of rats underwent ligation of the left anterior
descending coronary artery and were selected for study on
the basis of decreased fractional shortening compared to
sham-operated rats. These rats with heart failure had sig-
nificantly increased heart weights and markedly reduced
fractional shortening (from 50% in shams to 22% in heart
failure). Administration of CK-1827452 to anesthetized
rats with either heart failure or sham operations resulted in
a similar dose-related relative increase in fractional short-
ening (*20%), as compared to baseline. Interestingly,
sham-operated animals also demonstrated a significant
decrease in diastolic diameter at the highest dose.
Using a similar protocol as described above (Fig. 3),
another series of experiments were conducted in the two
labs of Drs. Stephen Vatner and David Kass in mongrel
dogs with heart failure due to myocardial infarction and
continuous rapid ventricular pacing. After 5–6 weeks of
post-myocardial infarction pacing to establish heart failure,
infusion of CK-1827452 produced significant improve-
ments in multiple parameters at both 15 min and 4 h. There
were marked increases in LV wall thickening (30–40%
change from baseline), fractional shortening (30–40%),
stroke volume (50–60%), and cardiac output (20–25%).
These improvements in cardiac function were associated
with more favorable hemodynamics, including decreased
left atrial pressure, left ventricular end-diastolic pressure,
total peripheral resistance, and heart rate with no change in
mean arterial or left ventricular systolic pressure. Impor-
tantly, there were no significant changes in coronary blood
flow, coronary sinus oxygen content, or myocardial oxygen
consumption (MVO2). Stroke work increased over 60% in
the context of no increase in oxygen demand, resulting in a
25–30% increase in cardiac efficiency. Consistent with the
mechanism of action, the systolic ejection time increased,
Fig. 3 Schematic diagram of
dog model of heart failure
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reflecting the increased duration of contraction observed in
the pre-clinical studies, with no change in the velocity of
contraction (dP/dt). These findings confirmed the thera-
peutic hypothesis that cardiac myosin activators could
improve cardiac function without compromising myocar-
dial oxygen demand given the absence of changes in
cellular calcium homeostasis.
Rapid pacing of dogs produces heart failure but without
significant left ventricular hypertrophy unlike the situation
most common in human heart failure where left ventricular
hypertrophy accompanies progressive ventricular dilata-
tion. In addition, since the mechanism of action increases
the duration of systole, there were questions of how this
drug would perform in the setting of left ventricular
hypertrophy and diastolic dysfunction. To address this
question, Dr. Stephen Vatner and colleagues performed
another series of experiments using a similar instrumenta-
tion protocol in mongrel dogs that underwent aortic
banding to produce a spectrum of cardiac abnormalities
ranging from severe left ventricular hypertrophy to
decompensated heart failure (Fig. 5) [22]. In dogs with
severe left ventricular hypertrophy without heart failure,
CK-1827452 produced an increased systolic ejection time,
as well as increased ventricular wall thickening, associated
with only transient increases in fractional shortening, and
stroke volume. As with prior studies in animals with heart
failure, dogs with left ventricular hypertrophy and heart
failure had increases in systolic ejection time, systolic wall
thickening, fractional shortening and stroke volume in
response to CK-1827452, associated with reductions in left
ventricular end-diastolic pressure, mean left atrial pressure,
and heart rate. Importantly, there was no change in the
epicardial-to-endocardial blood flow ratio or myocardial
oxygen demand during CK-1827452 infusion as compared
to baseline in dogs either with heart failure or left ven-
tricular hypertrophy. Thus, cardiac efficiency again
improves in this model of heart failure plus left ventricular
hypertrophy. In sum, these animal studies provided the
support for the potential benefit of CK-1827452 in the
treatment of heart failure and encouraged investigation of
this agent in humans.
The first-in-human study (CY1111) with CK-1827452
was initially presented as a late-breaking clinical trial at the
Heart Failure Society of America by Dr. John Teerlink
[23]. The primary objective of the study was to determine
the maximally tolerated dose (MTD) and plasma concen-
trations of CK-1827452 administered as a 6 h intravenous
infusion, while secondary objectives included evaluation of
its pharmacodynamics (including its effect on left ven-
tricular systolic function as assessed by echocardiography),
pharmacokinetics, and safety and tolerability. This study
enrolled healthy men in four ascending dose cohorts
(n = 34 subjects) who received a 6-h double-blind infusion
once each week for four weeks. Each treatment sequence
consisted of three ascending CK-1827452 doses and a
placebo infusion randomized into each treatment sequence,
where the low dose of each subsequent cohort was the high
dose from the prior cohort; modifications of the dosing
schedule were made as the MTD was achieved (Table 1).
CK-1827452 was studied at 0.005, 0.015, 0.025, 0.0625,
0.125, 0.25, 0.5, 0.625, 0.75 and 1.0 mg/kg/h. Transtho-
racic echocardiograms were obtained at baseline and after
6 h of infusion, as well as other time-points, and over-read
without knowledge of time or treatment by a panel of
cardiologists. Consistent with its mechanism of action, a
linear dose-related increase in LV systolic ejection time
was observed, with an almost perfect correlation between
plasma concentrations and systolic ejection time
(r2 = 0.97) [24]. At the MTD of 0.5 mg/kg/h, statistically
significant increases in LV systolic function were demon-
strated with absolute increases in ejection fraction and
fractional shortening of 6.8% (P \ 0.0001) and 9.2%
(P \ 0.0001), respectively. These increases in indices of
left ventricular function were associated with a mean
84 ms prolongation of systolic ejection time (P \ 0.0001),
and directly correlated with dose, and even more directly
with plasma concentration (r2 = 0.93 for LV fractional
shortening; r2 = 0.90 for ejection fraction) [24].
Fig. 5 Schematic diagram of
dog model of left ventricular
hypertrophy and heart failure
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Furthermore, there were direct relationships between the
systolic ejection time and both measures of ventricular
systolic function (r2 = 0.92 for LV fractional shortening;
r2 = 0.94 for ejection fraction). The very close relationship
between the plasma concentrations of CK-1827452 and
the systolic ejection time and the improvements in ven-
tricular function suggest that the effect on cardiac function
after dosing with this drug may be reliably observed and
predictable.
In this first-in-human study, [23, 25] at the maximally
tolerated dose (MTD) of 0.5 mg/kg/h for 6 h and below,
CK-1827452 was well tolerated when compared to pla-
cebo. In addition, CK-1827452 was clinically well
tolerated at 0.625 mg/kg/h for 6 h but too few volunteers
received this dose to define it according to protocol as the
MTD. By design, the study found doses that were not well
tolerated; three patients receiving the 0.75 and 1.0 mg/kg/h
doses developed signs and symptoms of myocardial
ischemia most likely due to excessive prolongation of the
systolic ejection time, causing decreased diastolic coronary
perfusion and decreased diastolic filling. This anticipated
response to the excessive pharmacologic effect of an over-
dose resulted in premature discontinuation of study drug
infusion in three out of the four patients at these dose levels
with rapid and complete resolution of abnormalities.
Importantly, no ‘‘off-target’’ adverse effects were noted
even at these extreme doses. At doses up to and through
0.5 mg/kg/h, there were no dose-related changes versus
placebo in heart rate or the electrocardiographic PR, and
the QT or corrected QT intervals actually shorten. Up to
and including the MTD, there was no dose-related increase
in the overall incidence of adverse events. In this study, the
cardiac myosin activator, CK-1827452, increased LV sys-
tolic function by a unique mechanism, directly increasing
systolic ejection time rather than contraction velocity.
These first-in-human data recapitulate the pharmacody-
namic effects in normal animals and animals with heart
failure, in support of the putative mechanism of action and
the potential clinical utility of CK-1827452 in patients with
heart failure.
Interim results from the first study of CK-1827452 in
patients with heart failure (CY1121) were initially pre-
sented by Dr. John Cleland at the European Society of
Cardiology Heart Failure Congress [26] and subsequently
at the European Society of Cardiology and Heart Failure
Society of America [27] meetings. The primary objective
of the study was to evaluate the safety and tolerability of
CK-1827452 administered as an intravenous infusion to
patients with stable heart failure, while secondary objec-
tives included evaluation of its pharmacodynamics
(including its effect on left ventricular systolic function as
assessed by echocardiography) and pharmacokinetics.
Patients were eligible for the study if they had a clinical
diagnosis of heart failure, an ejection fraction less than
40%, normal sinus rhythm, and a stable drug regimen,
including an ACE inhibitor or ARB, beta blocker, and
diuretics, if necessary. Patients with a cardiovascular hos-
pitalization within 6 weeks of entry or CCS class III or IV
angina were excluded. Patients were randomized sequen-
tially into each dose cohort, where each patient would
receive one of three active ascending CK-1827452 doses
with a placebo infusion randomly interspersed in the
sequence of doses; doses were separated by at least a week.
Loading doses and maintenance doses were modeled on the
basis of the pharmacokinetic data derived from the previ-
ously described CY1111 study [23]. Importantly, the
pharmacokinetics of the healthy volunteers were found to
Table 1 Dosing table for cohorts 1–4 in the CY1111 study in healthy
male volunteers [23]
Cohort CK-1827452 (mg/kg/h)
X Y Z
1 0.005 0.015 0.025
2 0.025 0.0625 0.125
3 0.125 0.25 0.50
4 0.50 1.0/0.75/0.625a 0.625
a Doses were adjusted as maximally tolerated dose was achieved
Table 2 Dosing table for
cohorts 1–3 in the CY1121
study in patients with heart
failure [26]
a Plasma concentrations
predicted based upon findings
from CY1111 study in healthy
volunteers [23]
Loading dose
(mg/kg)
Maintenance
dose (mg/kg)
Predicted Cmax
(median)a (ng/ml)
Measured Cmax
(median) (ng/ml)
Cohort 1
1 h ? 1 h
0.125 0.0625 90 93
0.25 0.125 175 177
0.50 0.25 320 331
Cohort 2
1 h ? 1 h
0.50 0.25 320 331
0.75 0.375 500 578
1.0 0.5 650 613
Cohort 3
1 h ? 23 h
0.25 0.025 175 155
0.5 0.05 320 289
1.0 0.1 650 625
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be highly predictive of the pharmacokinetics of the patients
with heart failure (see Table 2), and across the range of
plasma concentrations evaluated, the pharmacokinetics of
CK-1827452 were generally linear with respect to dose.
The CY1121 study is on-going, so the only complete
interim data available at this time are from the first three
cohorts. As with the healthy volunteer study, there were
pronounced, dose- and concentration-dependent increases
in the systolic ejection time, supporting the mechanism of
action of this cardiac myosin activator, but the proportion of
the cardiac cycle dedicated to ejection remained relatively
constant, due to the decline in heart rate at higher concen-
trations. There were concentration-dependent increases in
multiple measures of cardiac systolic function (Doppler-
derived stroke volume, fractional shortening, and ejection
fraction; all P \ 0.0001 for correlation with CK-1827452
concentration, except ejection fraction, P \ 0.05). The
Doppler-derived stroke volume significantly increased by
approximately 20% in the setting of a 10% decrease in heart
rate, resulting in a marked increase in cardiac output, ini-
tially evident at low-to-moderate concentrations. The
fractional shortening increased by about 23% at the higher
concentrations, while there were no significant increases in
ejection fraction although a concentration-dependent trend
toward increase did reach statistical significance. In addi-
tion, there were statistically significant correlations between
CK-1827452 concentration and decreases in left ventricular
end-systolic volume (P \ 0.05), while decreases in left
ventricular end-diastolic volume were not statistically sig-
nificant. The safety data from this preliminary analysis
suggest that CK-1827452 was well tolerated with no serious
adverse events reported in heart failure patients exposed to
the intended range of doses and plasma concentrations. The
interim findings from this first study of CK-1827452 in
patients with heart failure clearly demonstrated improve-
ments in cardiac function, which were directly related to the
plasma concentration of the drug.
Future directions
The findings from these Phase I and IIa studies provide the
basis of considerable enthusiasm for this new pharmaco-
logic class of cardiac myosin activators. Cytokinetics, Inc.
has conducted five Phase 1 clinical studies of CK-1827452
in healthy subjects, including a study of oral bioavailability
[28]. In this study, each healthy male volunteer (n = 8)
received four doses of CK-1827452 (0.125 mg/kg/h intra-
venous, 0.125 mg/kg oral liquid formulation, 0.125 mg/kg
oral capsule fasted, and 0.125 mg/kg oral capsule fed), and
blood samples were obtained for thorough pharmacokinetic
study. There was no evidence of first-pass metabolism, with
absolute bioavailability of all formulations approaching
100% and no effect of food on overall bioavailability. In
addition, it was well tolerated in all formulations with no
significant safety issues. Its absorption was very rapid
though, which led to efforts to develop a modified release
formulation. Subsequent studies performed with modified-
release prototype formulations led to the selection of one
prototype for further development and support the potential
of CK-1827452 as an oral therapy for chronic heart failure.
Other Phase IIa studies are also underway including a study
of the safety and tolerability of intravenous and oral for-
mulations in patients with ischemic cardiomyopathy, and
another study in stable heart failure patients undergoing
cardiac catheterization to evaluate ventricular performance
and myocardial oxygen consumption [29].
Cardiac myosin activators represent a novel therapeutic
approach to improving cardiac performance. By acceler-
ating the transition of the actin–myosin complex from
the weakly-to-the-strongly bound state and inhibiting the
non-productive hydrolysis of ATP, these agents increase
the ability of the heart to perform the work of pumping
blood without altering calcium homeostasis or increasing
cAMP. The absence of these effects on myocyte calcium
suggests that cardiac myosin activators may not increase
arrhythmias, myocardial oxygen demand, and ischemia, as
observed with the currently available inotropes (e.g., mil-
rinone and dobutamine). Studies in rats, dogs, and humans
have all supported the hypothesis of this beneficial effect
on cardiac function with a consistent relationship between
drug concentration and the duration of systolic ejection, a
measure of the mechanism of action. Improvements in
multiple measures of myocardial function, such as frac-
tional shortening and stroke volume, have been demon-
strated in all species, and in the dog, were associated with
no change in myocardial oxygen consumption and thus an
increase in myocardial efficiency. Finally, a few studies in
healthy volunteers and patients with heart failure showed
that CK-1827452 could safely increase cardiac perfor-
mance with no evidence of arrhythmias or ischemia at
therapeutic doses. For the greater than half a million
patients who are admitted each year with heart failure and
decreased LV systolic function, as well as the half million
patients undergoing cardiac surgery and others requiring
critical care inotropic support, the potential uses of a
safe intravenous agent are large. In addition, for the
millions of patients with chronic heart failure and reduced
LV function, cardiac myosin activators offer the promise
of a safe and effective treatment to address one of the
underlying causes of heart failure. Phase III studies are
being planned to test whether CK-1827452 will fulfill that
promise.
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